更正：开发一种优化的 AAV2/5 基因治疗载体，用于治疗因 RPE65 缺陷导致的 Leber 先天性羊角疯。

IF 4.6 3区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Gene Therapy Pub Date : 2024-07-12 DOI:10.1038/s41434-024-00463-z

A. Georgiadis, Y. Duran, J. Ribeiro, L. Abelleira-Hervas, S. J. Robbie, B. Sünkel-Laing, S. Fourali, A. Gonzalez-Cordero, E. Cristante, M. Michaelides, J. W. B. Bainbridge, A. J. Smith, R. R. Ali

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

查看原文本刊更多论文

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Gene Therapy 医学-生化与分子生物学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Gene Therapy covers both the research and clinical applications of novel therapeutic techniques based on a genetic component. Over the last few decades, significant advances in technologies ranging from identifying novel genetic targets that cause disease through to clinical studies, which show therapeutic benefit, have elevated this multidisciplinary field to the forefront of modern medicine.